左西孟旦注射液和多巴酚丁胺治疗急性失代偿性心力衰竭的血液动力学和疗效对比分析  

COMPARISON OF HEMODYNAMICS AND CURATIVE EFFECT ON ACUTE DECOMPENSATED HEART FAILURE TREATED BY ZUOXI MENGDAN INJECTION AND DOBUTAMINE

作　　者：郭明[1] 唐宇[1] 孙卫平 Guo Ming;Tang Yu;Sun Weiping(Department of Cardiology,Beijing Luhe Hospital,Capital Medical University,Beijing 101149,China)

机构地区：[1]首都医科大学附属潞河医院心内科,北京市101149

出　　处：《中国煤炭工业医学杂志》2018年第3期240-244,共5页Chinese Journal of Coal Industry Medicine

基　　金：北京市通州区科委课题项目(编号:KJ2015CX004-03)

摘　　要：目的对比分析左西孟旦注射液和多巴酚丁胺治疗急性失代偿性心力衰竭的血液动力学和疗效。方法我院2015年2月—2017年10月收治的82例急性失代偿性心力衰竭患者,通过简单随机分组方法分为二组对照组和观察组,每组41例,患者入院后均接受常规治疗,对照组接受多巴酚丁胺治疗,观察组接受左西孟旦注射液治疗,观察和比较二组患者治疗效果。结果观察组的总有效率92.68%(38/41),对照组的总有效率78.05%(32/41),观察组高于对照组,差异有统计学意义(P<0.05);治疗前,对照组和观察组的NE、ET-1和NT-proBNP等血液学指标差异无统计学意义(P>0.05);治疗后,观察组的NE、ET-1和NTproBNP等血液学指标低于对照组,差异有统计学意义(P<0.05);观察组不良反应的总发生率9.76%(4/41),对照组不良反应的总发生率21.95%(9/41),观察组低于对照组,差异有统计学意义(P<0.05)。结论左西孟旦注射液治疗急性失代偿性心力衰竭,其疗效突出,患者血清学指标更为稳定,且安全性高,应用价值高。Objective To analyze the blood flow and efficacy of Levosimendan injection and Dobutamine selected in author＇s hospital from February 2015 to October 2017,and divided into 2 groups according to their treatment（control group vs study group）,41 cases in each group.All the patients received routine treatment after admission,and the control group received Dobutamine treatment,while study group received Levosimendan injection treatment.And then the treatment effects of the two groups of patients were observed and compared.Results The total effective rate of the study group was 92.68%（38/41）,and the total effective rate of the control group was 78.05%（32/41）,and the study group was significantly higher than the control group.The difference was statistically significant（P〈0.05）.Before treatment,there was no significant difference in hematological indexes,such as NE,ET-1 and NT-proBNP in the control group and the study group,and no significant difference（P〉0.05）.After treatment,the hematological indexes such as NE,ET-1 and NT-proBNP in the study group were lower than those of the control group,the difference was statistically significant（P〈0.05）.The total incidence of adverse reactions in the study group was 9.76%（4/41）,and the total incidence of adverse reactions in the control group was 21.95%（9/41）,and the study group was lower than the control group.The difference was statistically significant（P〈0.05）.Conclusion It is recommended that the clinical treatment of acute decompensated heart failure should be treated with Levosimendan injection.The curative effect is outstanding,serological indicators of patients are more stable,and the safety is high,and the application value is high.

关 键 词：急性失代偿性心力衰竭 左西孟旦注射液 多巴酚丁胺 

分 类 号：R541.6[医药卫生—心血管疾病]